Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CTSL | P07711 | 4/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18265983 | 0.82 | ALDH1A1 (0.51) | CTSSCTSLCTSBALDH1A1CTSK | |
| SCHEMBL19852095 | 0.80 | ALDH1A1 (0.46) | CTSSCTSLCTSBALDH1A1CTSK | |
| SCHEMBL19852253 | 0.80 | ALDH1A1 (0.46) | CTSSCTSLCTSBALDH1A1CTSK | |
| SCHEMBL19852396 | 0.79 | SLC15A1 (0.44) | CTSSALDH1A1AAK1MAPK1L3MBTL1 | |
| SCHEMBL19852382 | 0.78 | CTSK (0.45) | CTSSCTSLCTSBALDH1A1CTSK | |
| SCHEMBL23135770 | 0.76 | ALDH1A1 (0.55) | CTSSCTSBALDH1A1CTSKKMT2A | |
| SCHEMBL15114576 | 0.76 | ALDH1A1 (0.55) | CTSSCTSBALDH1A1CTSKKMT2A | |
| SCHEMBL22432070 | 0.76 | ALDH1A1 (0.55) | CTSSCTSBALDH1A1CTSKKMT2A | |
| SCHEMBL20465366 | 0.73 | ALDH1A1 (0.47) | CTSSCTSLCTSBALDH1A1CTSK | |
| SCHEMBL9011978 | 0.73 | ALDH1A1 (0.50) | CTSSCTSLCTSBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640725-B2 | Thermocleavable friction modifiers and methods thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180037840-A1 | THERMOCLEAVABLE FRICTION MODIFIERS AND METHODS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037840-A1 | THERMOCLEAVABLE FRICTION MODIFIERS AND METHODS THEREOF | F12, F5, F3 | CTSS 4317/4885CTSL 4557/4885CTSB 4287/4885 |
| US-10640725-B2 | Thermocleavable friction modifiers and methods thereof | F12, F5, F3 | CTSS 4317/4885CTSL 4557/4885CTSB 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.